177 related articles for article (PubMed ID: 38549499)
21. Real-world management patterns in
Lampaki S; Mountzios G; Georgoulias V; Rapti A; Xanthakis I; Baka S; Mavroudis D; Samantas E; Athanasiadis E; Zagouri F; Charpidou A; Somarakis A; Papista C; Nikolaou A; Anastasopoulou E; Paparepa Z; Syrigos KN
Future Oncol; 2022 Sep; 18(28):3151-3164. PubMed ID: 35929414
[TBL] [Abstract][Full Text] [Related]
22. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.
Tanaka K; Asahina H; Kishimoto J; Miyata Y; Uchida T; Watanabe K; Hamai K; Harada T; Tsubata Y; Sugawara S; Kobayashi K; Sugio K; Oizumi S; Okamoto I
Eur J Cancer; 2021 May; 149():14-22. PubMed ID: 33813328
[TBL] [Abstract][Full Text] [Related]
23. Clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation.
Hu X; Chen W; Li X; Zhao C; Zhang C; Xiong F; Wu H
Ann Palliat Med; 2019 Nov; 8(5):525-531. PubMed ID: 31865717
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the efficacy and safety of first-line treatments based on clinicopathological characteristics for patients with advanced epidermal growth factor receptor mutated non-small-cell lung cancer: A systematic review and network meta-analysis.
Yang F; Zhang W; Shang X; Liu N; Ma X; Qin J; Zhang Y; Liu Y; Wang X
Crit Rev Oncol Hematol; 2022 Sep; 177():103760. PubMed ID: 35870763
[TBL] [Abstract][Full Text] [Related]
25. Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer.
Lin YT; Tsai TH; Wu SG; Liu YN; Yu CJ; Shih JY
Lung Cancer; 2020 Jul; 145():1-9. PubMed ID: 32387812
[TBL] [Abstract][Full Text] [Related]
26. Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC.
Frampton JE
Target Oncol; 2022 May; 17(3):369-376. PubMed ID: 35713772
[TBL] [Abstract][Full Text] [Related]
27. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in
Okura N; Nishioka N; Yamada T; Taniguchi H; Tanimura K; Katayama Y; Yoshimura A; Watanabe S; Kikuchi T; Shiotsu S; Kitazaki T; Nishiyama A; Iwasaku M; Kaneko Y; Uchino J; Uehara H; Horinaka M; Sakai T; Tanaka K; Kozaki R; Yano S; Takayama K
Clin Cancer Res; 2020 May; 26(9):2244-2256. PubMed ID: 31953310
[TBL] [Abstract][Full Text] [Related]
28. Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M.
Zhao S; Li X; Zhao C; Jiang T; Jia Y; Shi J; He Y; Li J; Zhou F; Gao G; Li W; Chen X; Su C; Ren S; Zhou C
Lung Cancer; 2019 Feb; 128():33-39. PubMed ID: 30642450
[TBL] [Abstract][Full Text] [Related]
29. Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M-positive NSCLC: A retrospective study.
Zhou B; Gong Q; Li B; Qie HL; Li W; Jiang HT; Li HF
J Clin Pharm Ther; 2022 May; 47(5):643-651. PubMed ID: 35023208
[TBL] [Abstract][Full Text] [Related]
30. Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment.
Provencio M; Serna-Blasco R; Franco F; Calvo V; Royuela A; Auglytė M; Sánchez-Hernández A; de Julián Campayo M; García-Girón C; Dómine M; Blasco A; Sánchez JM; Oramas J; Bosch-Barrera J; Sala MÁ; Sereno M; Ortega AL; Chara L; Hernández B; Padilla A; Coves J; Blanco R; Balsalobre J; Mielgo X; Bueno C; Jantus-Lewintre E; Molina-Vila MÁ; Romero A
Eur J Cancer; 2021 May; 149():61-72. PubMed ID: 33831609
[TBL] [Abstract][Full Text] [Related]
31. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
[TBL] [Abstract][Full Text] [Related]
32. Overall Survival with Osimertinib in Untreated,
Ramalingam SS; Vansteenkiste J; Planchard D; Cho BC; Gray JE; Ohe Y; Zhou C; Reungwetwattana T; Cheng Y; Chewaskulyong B; Shah R; Cobo M; Lee KH; Cheema P; Tiseo M; John T; Lin MC; Imamura F; Kurata T; Todd A; Hodge R; Saggese M; Rukazenkov Y; Soria JC;
N Engl J Med; 2020 Jan; 382(1):41-50. PubMed ID: 31751012
[TBL] [Abstract][Full Text] [Related]
33. Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: Osimertinib vs. first-generation EGFR tyrosine kinase inhibitors.
Zhou Y; Wang B; Qu J; Yu F; Zhao Y; Li S; Zeng Y; Yang X; Chu L; Chu X; Li Y; Zou L; Guo T; Ye L; Liang F; Wang S; Liu Q; Ni J; Zhu Z
Lung Cancer; 2020 Dec; 150():178-185. PubMed ID: 33186860
[TBL] [Abstract][Full Text] [Related]
34. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
Mu Y; Hao X; Xing P; Hu X; Wang Y; Li T; Zhang J; Xu Z; Li J
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2427-2433. PubMed ID: 32385709
[TBL] [Abstract][Full Text] [Related]
35. Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung Cancer.
Auliac JB; Saboundji K; Andre M; Madelaine J; Quere G; Masson P; Vergnenegre A; Lamy R; Raymond S; Chiappa AM; Hauss PA; Fournel P; Corre R; Chouaid C
Target Oncol; 2019 Jun; 14(3):307-314. PubMed ID: 31119481
[TBL] [Abstract][Full Text] [Related]
36. Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status.
Nakashima K; Kimura M; Akamatsu H; Daga H; Imai H; Taira T; Ko R; Hisamatsu Y; Nishino K; Sugimoto T; Miyashita Y; Takahashi T;
Jpn J Clin Oncol; 2019 Jul; 49(7):671-675. PubMed ID: 30920616
[TBL] [Abstract][Full Text] [Related]
37. Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases.
Yu X; Sheng J; Pan G; Fan Y
Int J Cancer; 2021 Sep; 149(5):1121-1128. PubMed ID: 33970485
[TBL] [Abstract][Full Text] [Related]
38. Abivertinib in patients with T790M-positive advanced NSCLC and its subsequent treatment with osimertinib.
Wang H; Pan R; Zhang X; Si X; Wang M; Zhang L
Thorac Cancer; 2020 Mar; 11(3):594-602. PubMed ID: 31943845
[TBL] [Abstract][Full Text] [Related]
39. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.
Miyashita Y; Ko R; Shimada N; Mitsuishi Y; Miura K; Matsumoto N; Asao T; Shukuya T; Shibayama R; Koyama R; Takahashi K
Thorac Cancer; 2021 Feb; 12(3):329-338. PubMed ID: 33219754
[TBL] [Abstract][Full Text] [Related]
40. Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib.
Hochmair MJ; Buder A; Schwab S; Burghuber OC; Prosch H; Hilbe W; Cseh A; Fritz R; Filipits M
Target Oncol; 2019 Feb; 14(1):75-83. PubMed ID: 30539501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]